Discriminant ratio and biometrical equivalence of measured vs. calculated apolipoprotein B100 in patients with T2DM

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendations

(2011) Jacques Genest et al.   CANADIAN JOURNAL OF CARDIOLOGY

log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males

(2011) Michel P Hermans et al.   Cardiovascular Diabetology

Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence

(2011) Michel P Hermans et al.   Cardiovascular Diabetology

Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk

(2011) Terry A. Jacobson   MAYO CLINIC PROCEEDINGS

Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians

(2011) Michel P. Hermans et al.   Therapeutic Advances in Chronic Disease

Lipoprotein Management in Patients With Cardiometabolic Risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation

(2008) J. D. Brunzell et al.   DIABETES CARE